Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 8% of the time (780 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 10% (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: cancertherapybreastrecentchest
  Phrases that lowered it: participantinvestigateefficacysubjects whotuberculosis
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 13.0% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: quadruple (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 45 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Responsible party: not given (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Number of arms: 3 (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports marked serious: 84.8% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 60 (lowers risk) · Sponsor's track record
• Disease area, infectious disease: Yes (lowers risk) · Disease area
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa NCT01635764 · started 2012 · scored riskier than 13% of active trials completed
• Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa NCT01468207 · started 2011 · scored riskier than 22% of active trials completed
• Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa NCT01468233 · started 2011 · scored riskier than 20% of active trials completed
• Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa NCT02904902 · started 2016 · scored riskier than 17% of active trials completed
• Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) NCT05103423 · started 2021 · scored riskier than 34% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.